FindTrial
Sign In

A study on the immune characteristics of idiopathic inflammatory myopathy and its clinical relevance based on non-targeted metabolomics of peripheral blood mononuclear cells

A study on the immune characteristics of idiopathic inflammatory myopathy and its clinical relevance based on non-targeted metabolomics of peripheral blood mononuclear cells

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121383
Enrollment
Unknown
Registered
2026-03-30
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic inflammatory myopathy

Interventions

Idiopathic Inflammatory Myopathy (IIMs) Patient Group:None
Healthy Control (HC) Group:None

Sponsors

Shanxi Bethune Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Compliant with EULAR/ACR 2017 IIM classification standards;

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Any history of acute or chronic infection or chronic inflammatory disease; 3. Any malignant tumor and current malignant tumor; 4. Chronic diseases such as coronary heart disease, diabetes, and hypertension; 5. Those with other rheumatic diseases.

Design outcomes

Primary

MeasureTime frame
Correlation between differentially expressed metabolites and clinical symptoms;Correlation between differentially expressed metabolites and laboratory parameters;—

Countries

China

Contacts

Public ContactXu Ke

Shanxi Bethune Hospital

xuke@sxbqeh.com.cn+86 351 2170930

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026